A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

British Journal of Haematology

Volumn 114, Issue 1, 2001, Pages 111-113

  Mesa, Ruben A ^a   Tefferi, Ayalew ^a   Elliott, Michelle A ^a   Clark Hoagland, H ^a   Call, Timothy G ^a   Schroeder, Georgene S ^a   Yoon, Soo Young ^a   Li, Chin Yang ^a   Gray, Leigh A ^a   Margolin, S ^b   Christopher Hook, C ^a  

^a MAYO CLINIC   (United States)

^b Marnac Inc   (United States)

Author keywords

Cytokines; Erythropoiesis; Myelofibrosis with myeloid metaplasia; Pirfenidone; Stem cells

Indexed keywords

PIRFENIDONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; HUMAN; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; BONE MARROW; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PROSPECTIVE STUDIES; PYRIDONES; TREATMENT FAILURE;

EID: 0034928733     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02883.x     Document Type: Article

References (12)

1. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia
2. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone
3. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
4. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level
5. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis
6. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts
7. The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders
8. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor beta in patients with myelofibrosis with myeloid metaplasia
9. Transforming growth factor beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis
10. Evaluation and clinical correlations of bone ma0rrow angiogenesis in myelofibrosis with myeloid metaplasia
11. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent pirfenidone: Results of a prospective, open-label phase II study
12. Myelofibrosis with myeloid metaplasia